JP2012513471A - アルツハイマー病および癌の治療のためのクマリン系化合物 - Google Patents

アルツハイマー病および癌の治療のためのクマリン系化合物 Download PDF

Info

Publication number
JP2012513471A
JP2012513471A JP2011543615A JP2011543615A JP2012513471A JP 2012513471 A JP2012513471 A JP 2012513471A JP 2011543615 A JP2011543615 A JP 2011543615A JP 2011543615 A JP2011543615 A JP 2011543615A JP 2012513471 A JP2012513471 A JP 2012513471A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
independently
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011543615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513471A5 (cg-RX-API-DMAC7.html
Inventor
レイ チュー,
ハキム ジャバラ,
ユエミン リー,
クリストファー チャド シェルトン,
Original Assignee
スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ filed Critical スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ
Publication of JP2012513471A publication Critical patent/JP2012513471A/ja
Publication of JP2012513471A5 publication Critical patent/JP2012513471A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2011543615A 2008-12-22 2009-12-21 アルツハイマー病および癌の治療のためのクマリン系化合物 Pending JP2012513471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13983008P 2008-12-22 2008-12-22
US61/139,830 2008-12-22
US25581909P 2009-10-28 2009-10-28
US61/255,819 2009-10-28
PCT/US2009/068989 WO2010075280A2 (en) 2008-12-22 2009-12-21 Coumarin-based compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014196911A Division JP2015038103A (ja) 2008-12-22 2014-09-26 アルツハイマー病および癌の治療のためのクマリン系化合物

Publications (2)

Publication Number Publication Date
JP2012513471A true JP2012513471A (ja) 2012-06-14
JP2012513471A5 JP2012513471A5 (cg-RX-API-DMAC7.html) 2013-01-31

Family

ID=41785813

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011543615A Pending JP2012513471A (ja) 2008-12-22 2009-12-21 アルツハイマー病および癌の治療のためのクマリン系化合物
JP2014196911A Pending JP2015038103A (ja) 2008-12-22 2014-09-26 アルツハイマー病および癌の治療のためのクマリン系化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014196911A Pending JP2015038103A (ja) 2008-12-22 2014-09-26 アルツハイマー病および癌の治療のためのクマリン系化合物

Country Status (6)

Country Link
US (2) US20110306605A1 (cg-RX-API-DMAC7.html)
EP (1) EP2379504A2 (cg-RX-API-DMAC7.html)
JP (2) JP2012513471A (cg-RX-API-DMAC7.html)
AU (1) AU2009330124A1 (cg-RX-API-DMAC7.html)
CA (1) CA2747811A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010075280A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542571B1 (en) 2010-03-03 2016-05-25 The University of British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2013071267A1 (en) * 2011-11-10 2013-05-16 Cangene U.S., Incorporated Compositions and methods for treating alzheimer's disease
TWI571207B (zh) 2011-06-26 2017-02-21 安麗托克斯公司 用於條件化動物飼料之寒冷天氣調配物
CN102584841B (zh) * 2011-12-16 2014-11-12 浙江工业大学 一种喹啉香豆素衍生物及其制备方法及用途
CN102731458B (zh) * 2012-07-12 2014-03-26 中国科学院南海海洋研究所 双异戊烯基香豆素及其制备方法和应用
CN105884681A (zh) * 2014-10-24 2016-08-24 江苏师范大学 一种聚乙二醇中吡啶衍生物的合成方法
CN104529987B (zh) * 2014-12-04 2016-08-10 中国人民解放军第四军医大学 一类4-羟基双香豆素类化合物及其应用
JP6509079B2 (ja) * 2015-08-27 2019-05-08 株式会社ファンケル ヘリピロンAを有効成分とするPGC1α産生促進剤
CN108774204A (zh) * 2018-06-13 2018-11-09 中国人民解放军第四军医大学 3,3′-(3,5二氟苯亚甲基)-双-4-羟基香豆素及其应用
CN112898278B (zh) * 2019-11-19 2022-05-13 广东医科大学 Sigma-2荧光配体的制备及应用
CN111848565B (zh) * 2020-07-24 2023-01-31 华润三九医药股份有限公司 单萜基双香豆素类化合物、药物组合物及其制备方法和用途
CN112645922B (zh) * 2020-12-24 2022-01-07 中国人民解放军空军军医大学 香豆素类化合物、制备方法及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE654291A (cg-RX-API-DMAC7.html) * 1963-10-31 1965-02-01
WO2003029237A1 (en) * 2001-10-01 2003-04-10 Pliva, Farmaceutska Industrija, Dionicko Drustvo Products of condensations of hydroxycoumarin derivatives with aromatic and aliphatic dialdehydes, their preparation and antiviral action thereof
JP2005002133A (ja) * 1993-02-05 2005-01-06 Pharmacia & Upjohn Co Llc レトロウイルス感染症の治療に有用な4−ヒドロキシ−ベンゾピラン−2−オンおよび4−ヒドロキシ−シクロアルキル[b]ピラン−2−オン
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
JP2007061093A (ja) * 2005-08-12 2007-03-15 Abgenomics Corp ペルオキシソーム増殖活性化受容体モジュレーター
WO2007082178A2 (en) * 2006-01-06 2007-07-19 Abgenomics Corporation Prostaglandin reductase inhibitors
JP2008526951A (ja) * 2005-01-14 2008-07-24 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 抗炎症活性を有するビス−(クマリン)化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE654291A (cg-RX-API-DMAC7.html) * 1963-10-31 1965-02-01
JP2005002133A (ja) * 1993-02-05 2005-01-06 Pharmacia & Upjohn Co Llc レトロウイルス感染症の治療に有用な4−ヒドロキシ−ベンゾピラン−2−オンおよび4−ヒドロキシ−シクロアルキル[b]ピラン−2−オン
WO2003029237A1 (en) * 2001-10-01 2003-04-10 Pliva, Farmaceutska Industrija, Dionicko Drustvo Products of condensations of hydroxycoumarin derivatives with aromatic and aliphatic dialdehydes, their preparation and antiviral action thereof
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
JP2008526951A (ja) * 2005-01-14 2008-07-24 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 抗炎症活性を有するビス−(クマリン)化合物
JP2007061093A (ja) * 2005-08-12 2007-03-15 Abgenomics Corp ペルオキシソーム増殖活性化受容体モジュレーター
WO2007082178A2 (en) * 2006-01-06 2007-07-19 Abgenomics Corporation Prostaglandin reductase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014012602; Chinese Pharm. J. 53, 2001, 85-95 *
JPN6014012603; J. Med. Chem. 50, 2007, 6316-6325 *

Also Published As

Publication number Publication date
EP2379504A2 (en) 2011-10-26
US20150133493A1 (en) 2015-05-14
WO2010075280A2 (en) 2010-07-01
JP2015038103A (ja) 2015-02-26
US20110306605A1 (en) 2011-12-15
AU2009330124A1 (en) 2011-07-14
WO2010075280A3 (en) 2010-08-19
CA2747811A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
JP2015038103A (ja) アルツハイマー病および癌の治療のためのクマリン系化合物
CN106167483B (zh) 可用于胆固醇动员的化合物、组合物和方法
KR101261305B1 (ko) 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
CA3191842A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2010002985A1 (en) Bmi-1 protein expression modulators
WO2014172638A2 (en) Inhibitors of deubiquitinating proteases
WO2006031894A2 (en) Methods of treating a disorder
CA2338275A1 (en) Integrin receptor antagonists
AU2013272429B2 (en) Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
EP2417136B1 (en) Imidazo [1,2-a] pyridine-6-carboxamide derivatives, their use for the treatment of colon cancer and their method of manufacture
JP6797408B2 (ja) 新規アルツハイマー病治療薬
JP2014210820A (ja) 癌及び神経変性疾患の治療又は予防方法
AU2009330131A1 (en) Compounds and methods for the treatment of pain and other diseases
CN107304200B (zh) 一种新的喜巴辛类似物及其在医药中的应用
WO2006099245A9 (en) Sirt inhibitors that bind to nad
US20250179024A1 (en) Amyloid and associated pathology modulators and methods thereof
JP2009513577A (ja) アミジン誘導体及びその薬剤としての使用
EP3648766A1 (en) Peptide and small molecule agonists of epha and their uses
CN110016069B (zh) 丹参酮iia哌嗪类化合物及其制备方法和用途
CN107304199A (zh) 一种新的喜巴辛类似物及其在医药中的应用
JP4003369B2 (ja) 抗癌剤
KR101608499B1 (ko) 4-니트로인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
KR20100066870A (ko) 신규한 6-인다졸릴아미노-3-니트로피리딘 유도체 화합물, 그의 제조방법 및 이를 포함하는 약제학적 조성물
WO2010051664A1 (zh) 7H-咪唑并[1,2-a]吡喃并[2,3-c]吡啶类衍生物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140725

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140825

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150309